[
    [
        {
            "time": "",
            "original_text": "2022年中药投资策略：挖掘“改革后基本面好转+大健康外延”个股",
            "features": {
                "keywords": [
                    "中药",
                    "投资策略",
                    "改革",
                    "基本面好转",
                    "大健康"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "中药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2022年中药投资策略：挖掘“改革后基本面好转+大健康外延”个股",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "多家上市公司入围19省区中成药集采，龙津药业斩获两连板",
            "features": {
                "keywords": [
                    "上市公司",
                    "中成药",
                    "集采",
                    "龙津药业",
                    "两连板"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "中成药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "多家上市公司入围19省区中成药集采，龙津药业斩获两连板",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "品牌中药OTC：看好政策支持、业绩确定、估值性价比高的稳健赛道投资机会",
            "features": {
                "keywords": [
                    "品牌中药",
                    "OTC",
                    "政策支持",
                    "业绩确定",
                    "估值性价比高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "中药",
                    "OTC"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "品牌中药OTC：看好政策支持、业绩确定、估值性价比高的稳健赛道投资机会",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]